Want to join the conversation?
$GILD said that its two Phase 3 clinical trials (Studies 108 & 110) met their primary objectives. $GILD stated that it plans to submit regulatory applications for tenofovir alafenamide for chronic hepatitis B virus in the US and the EU in 1Q16. The company plans to submit data from both studies for presentation to a scientific conference in 2016.
Visa ($V) set to release it earning after market close today. With new CEO resigning so close to the earnings, should we expect to see any surprises? Visa has been making strong moves with Visa Europe acquisition, partnership with PayPal and a 15% increase if quarterly dividends.
Kimberly Clark Corp ($KMB) has been in decline for most of the year, the stock has also not been getting any analyst love. Will today’s earnings break the trend? Revenue has been up and down in the last four quarters, let us see what this quarter brings.
$KMB down close to 4% after it misses on earnings and revenue. Forecasts are lower for the year.